EMA’s CHMP (Committee for Medicinal Products for Human Use) offered a positive opinion for GW Pharmaceuticals Plc (NASDAQ:GWPH)’s Type II variant of Epidyolex to treat seizures...
GW Pharmaceuticals PLC (NASDAQ:GWPH) posted a growth of 68.4% YoY to $121.3 million in revenues in Q2 2020. CEO of GW Pharmaceuticals, Justin Gover, said the...
The Home Office in the UK changed GW Pharmaceuticals PLC (NASDAQ:GWPH)’s Epidyolex to schedule 5 from schedule 2. However, different legislation will be enacted in the...